Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation    CVM   US1508375086

SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI : NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries

03/03/2015 | 10:17am US/Eastern

CEL-SCI COMPLETES KEY MILESTONE WITH CLEARANCE TO CONDUCT PHASE III TRIAL IN 21 COUNTRIES

Belarus is 21st country to clear CEL-SCI's trial for patient enrollment

Vienna, VA, February 27, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced the Ministry of Health of the Republic of Belarus has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Belarus is the 21st country to approve CEL-SCI's Phase III trial.

"This means that CEL-SCI has now reached a key milestone in this pivotal Phase III clinical trial, receiving clearance in the planned 20 countries in addition to the United States. Well over 10 countries have been added to the study since we dismissed the prior clinical research organization (CRO). With the very large increase in enrollment in the study under the new CRO, we now also see strong interest from doctors and clinical centers in other countries too. Therefore, we are working on further expanding this global trial beyond the 21 countries in which we are already cleared to conduct the study. We expect that expanding the geography of the trial will yet further accelerate patient recruitment," stated CEL-SCI Chief Executive Officer Geert Kersten.

About Multikine Phase III Study

The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.

About Multikine

Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase III clinical trial as a potential first-line treatment for advanced primary (not yet treated) head and neck cancer. If approved for use following completion of CEL-SCI's clinical development program for head and neck cancer, Multikine would be a different type of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors. CEL-SCI is aiming to complete enrollment of subjects to the Phase III head and neck cancer study by the end of 2015.

In October 2013, CEL-SCI announced that it had signed a CRADA (Cooperative Research and Development Agreement) with the U.S. Naval Medical Center, San Diego, to develop Multikine as a potential treatment for HIV/HPV co-infected men and women with peri-anal warts. The Phase I trial started enrolling patients in September 2014. CEL-SCI also entered into two new co-development agreements with Ergomed to further clinically develop Multikine for cervical dysplasia/neoplasia in HIV/HPV co-infected women and for peri-anal warts in HIV/HPV co-infected men and women.

About CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. CEL-SCI believes that the best way may be to activate the immune system of patients before they have received surgery, radiation and/or chemotherapy. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compared to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multikine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Navy under a CRADA.

CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential therapeutic vaccine against rheumatoid arthritis. CEL-SCI received a Phase I SBIR Grant from the National Institutes of Health to develop LEAPS as a potential treatment for rheumatoid arthritis with researchers from Rush University Medical Center in Chicago, Illinois. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

When used in this report, the words "intends," "believes," "anticipated", "plans" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2014. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

distributed by
React to this article
Latest news on CEL-SCI CORPORATION
10:17a CEL SCI : NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enro..
10:17a CEL SCI : NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Ph..
08:16a CEL SCI : Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for..
02:16aDJBritish American Tobacco PLC BAT submits notice of proposed offer for SouzaCr..
03/02 CEL SCI : gets clearance to conduct Phase III trial of cancer drug Multikine in ..
02/27 CEL SCI : NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management ..
02/27 CEL SCI : Completes Key Milestone with Clearance to Conduct Phase III Trial in 2..
02/27 CEL-SCI CORPORATION : (NYSE MKT: CVM), Arguably the Most Undervalued Phase III B..
02/27 CEL SCI : NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Fe..
02/25 CEL SCI : to Present at 3rd Annual Sachs Cancer Bio Partnering & Investment Foru..
Advertisement
Chart
Duration : Period :
CEL-SCI Corporation Technical Analysis Chart | CVM | US1508375086 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF